Axim Biotechnologies Inc (OTCMKTS:AXIM) reported that its CTO Lekhram Changoer presented the firm’s research at the 6th PSWC, held from May 21-24, 2017 in Stockholm. He presented under the program course on Drug Delivery and Targeting Sciences on two different topics. The first one was Chewing Gum; a unique delivery mechanism for hemp oil-derived CBD formulation targeting Irritable Bowel Syndrome Patients; and second one was chewing Gum; a unique delivery mechanism for CBD and THC formulations targeting spasticity and pain in Multiple Sclerosis patients.
This event was planned by International Pharmaceutical Federation, PSWC which is a major international global forum where scientists come at a common platform to network with key leaders from the pharma industry, government agencies, academia and public-private associations, and regulatory bodies.
Earlier Axim reported that information on the firm’s bioavailability trial on Dronabinol in a regulated-release, handy chewing gum form is now accessible on National Institutes of Health online site. This clinical trial will pave the scientific base for company and its controlled-substance API associate to co-advance a dronabinol-based functional, regulated-release chewing gum offering.
The latest dronabinol chewing gum offering will be bioequivalent to Marinol®, and it will be used to assist treat patients with chemotherapy led vomiting and nausea and AIDS patients witnessing weight and appetite loss.
The clinical trial is currently in preparation stage and is projected to register 50 healthy, non-smoking female and male, aged between 18 – 55 years.
AXIM emphasis remains on the research, development and manufacturing of cannabis-based pharma, cosmetic and nutraceutical products. Its major products include a CBD-based regulated release chewing gum CanChew®, which contains 50 mg of CBD experiencing clinical trials in subjects with IBS. Another product is MedChew Rx, which is a combination CBD and THC gum that is into clinical trials targeting spasticity and pain related with multiple sclerosis.
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies